Jeffrey S. Miller

45.9k citations

607 papers · 32.9k indexed · 8 hit papers · h-index 96

Immunology top 0.01%
Oncology top 0.05%
Hematology top 0.02%
Molecular Biology top 1%
Epidemiology top 1%

Co-authors: Daniel J. Weisdorf Bruce R. Blazar Sarah Cooley Michael R. Verneris Todd E. DeFor John E. Wagner Philip B. McGlave Valarie McCullar
Topics: Immune Cell Function and Interaction (348 papers)Hematopoietic Stem Cell Transplantation (176 papers)T-cell and B-cell Immunology (159 papers)
Cited by: Immunology Hematology Oncology
Journals: New England Journal of Medicine Proceedings of the National Academy of Sciences Nucleic Acids Research
Partner nations: United States United Kingdom Sweden

In The Last Decade

Jeffrey S. Miller

595 papers receiving 32.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

2005 1.4k citations Jeffrey S. Miller, Angela Panoskaltsis‐Mortari et al. Blood profile →
Exploring the NK cell platform for cancer immunotherapy

2020 864 citations Jeffrey S. Miller et al. profile →
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics

2010 805 citations Claudio G. Brunstein, Jeffrey S. Miller et al. Blood profile →
Tryptase Levels as an Indicator of Mast-Cell Activation in Systemic Anaphylaxis and Mastocytosis

1987 600 citations Jeffrey S. Miller et al. profile →
Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy

2004 597 citations Juliet N. Barker, Daniel J. Weisdorf et al. Blood profile →
Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector Function

2015 551 citations Frank Cichocki, Bree Foley et al. profile →
Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function

2011 491 citations Bree Foley, Sarah Cooley et al. Blood profile →
An Arabidopsis Cell Wall Proteoglycan Consists of Pectin and Arabinoxylan Covalently Linked to an Arabinogalactan Protein

2013 382 citations Jeffrey S. Miller et al. profile →

Peers

Countries citing papers authored by Jeffrey S. Miller

Since Specialization

Citations

This map shows the geographic impact of Jeffrey S. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey S. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey S. Miller more than expected).

Fields of papers citing papers by Jeffrey S. Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey S. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey S. Miller. The network helps show where Jeffrey S. Miller may publish in the future.

Co-authorship network of co-authors of Jeffrey S. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey S. Miller. A scholar is included among the top collaborators of Jeffrey S. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey S. Miller. Jeffrey S. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells 2024 ·Journal for ImmunoTherapy of Cancer ·(unknown),(unknown),(unknown),Sam C. Wang,(unknown),(unknown),(unknown),Tanya S. Freedman,Martin Felices,(unknown),(unknown),Jeffrey S. Miller,Bruce Walcheck	4
2	Immunotherapeutic Development of a Tri-Specific NK Cell Engager Recognizing BCMA 2023 ·SHILAP Revista de lepidopterología ·(unknown),Martin Felices,Behiye Kodal,Jeffrey S. Miller,Daniel A. Vallera	2
3	JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results 2023 ·Blood ·Joseph Pidala,Shernan G. Holtan,Kelly Walton,Jongphil Kim,Hany Elmariah,Asmita Mishra,Nelli Bejanyan,Taiga Nishihori,Farhad Khimani,Lia Perez,Rawan Faramand,Marco L. Davila,Claudio Anasetti,Daniel J. Weisdorf,Bruce R. Blazar,Jeffrey S. Miller,Veronika Bachanová,(unknown),Brian C. Betts	1
4	Proliferating Regulatory T Cells Are Associated with Poor Survival in Lymphoma Patients Treated with Autologous Hematopoietic Stem Cell Transplantation 2021 ·Transplantation and Cellular Therapy ·(unknown),Qing Cao,(unknown),Claudio G. Brunstein,Jeffrey S. Miller,Veronika Bachanová	1
5	GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts 2020 ·Blood ·Erica D. Warlick,Daniel J. Weisdorf,Daniel A. Vallera,(unknown),Dixie Lewis,(unknown),(unknown),Martin Felices,Jeffrey S. Miller	29
6	FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma 2020 ·Blood ·Jode Goodridge,Ryan Bjordahl,Sajid Mahmood,(unknown),Svetlana Gaidarova,Robert Blum,Frank Cichocki,(unknown),Greg Bonello,Tom Lee,Brian Groff,(unknown),Yu‐Waye Chu,Bruce Walcheck,Karl‐Johan Malmberg,Jeffrey S. Miller,Armin Rehm,Uta E. Höpken,Bahram Valamehr	34
7	Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors 2018 ·Clinical Cancer Research ·Kim Margolin,Chihiro Morishima,Vamsidhar Velcheti,Jeffrey S. Miller,Sylvia M. Lee,Ann W. Silk,Shernan G. Holtan,Andreanne M. Lacroix,Steven P. Fling,Judith C. Kaiser,Jack O. Egan,Monica Jones,Peter R. Rhode,Amy D. Rock,Martin A. Cheever,Hing C. Wong,Marc S. Ernstoff	146
8	Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37 2018 ·Cancer Immunology Research ·Dhifaf Sarhan,Keli L. Hippen,(unknown),(unknown),Xianghua Luo,Todd Lenvik,Julie Curtsinger,Zachary Davis,Bin Zhang,Sarah Cooley,Frank Cichocki,Bruce R. Blazar,Jeffrey S. Miller	93
9	Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation 2018 ·Blood ·Sarah Cooley,Peter Parham,Jeffrey S. Miller	97
10	Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML 2018 ·Clinical Cancer Research ·Andreas T. Björklund,Mattias Carlsten,Ebba Sohlberg,Lisa L. Liu,Trevor Clancy,Mohsen Karimi,Sarah Cooley,Jeffrey S. Miller,Monika Klimkowska,Marie Schaffer,Emma Watz,Kristina Wikström,Pontus Blomberg,Björn E. Wahlin,Marzia Palma,Lotta Hansson,Per Ljungman,Eva Hellström-Lindberg,Hans‐Gustaf Ljunggren,Karl‐Johan Malmberg	141
11	IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function 2016 ·Clinical Cancer Research ·Daniel A. Vallera,Martin Felices,Ron McElmurry,Valarie McCullar,Xianzheng Zhou,Joerg Uwe Schmohl,Bin Zhang,Alexander J. Lenvik,Angela Panoskaltsis‐Mortari,Michael R. Verneris,Jakub Tolar,Sarah Cooley,Daniel J. Weisdorf,Bruce R. Blazar,Jeffrey S. Miller	295
12	Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells 2016 ·Cancer Research ·Dhifaf Sarhan,Frank Cichocki,Bin Zhang,Ashley Yingst,Stephen R. Spellman,Sarah Cooley,Michael R. Verneris,Bruce R. Blazar,Jeffrey S. Miller	157
13	Umbilical cord blood–derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect 2015 ·Blood ·Claudio G. Brunstein,Jeffrey S. Miller,David H. McKenna,Keli L. Hippen,Todd E. DeFor,Darin Sumstad,Julie Curtsinger,Michael R. Verneris,Margaret L. MacMillan,Bruce L. Levine,James L. Riley,Carl H. June,Chap T. Le,Daniel J. Weisdorf,Philip B. McGlave,Bruce R. Blazar,John E. Wagner	303
14	Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent functionbreakdown → 2011 ·Blood ·Bree Foley,Sarah Cooley,Michael R. Verneris,(unknown),Julie Curtsinger,Xianghua Luo,Sandra López‐Vergès,Lewis L. Lanier,Daniel J. Weisdorf,Jeffrey S. Miller	491
15	Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kineticsbreakdown → 2010 ·Blood ·Claudio G. Brunstein,Jeffrey S. Miller,Qing Cao,David H. McKenna,Keli L. Hippen,Julie Curtsinger,Todd E. DeFor,Bruce L. Levine,Carl H. June,Pablo Rubinstein,Philip B. McGlave,Bruce R. Blazar,John E. Wagner	805
16	Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease 2007 ·Blood ·Claudio G. Brunstein,Juliet N. Barker,Daniel J. Weisdorf,Todd E. DeFor,Jeffrey S. Miller,Bruce R. Blazar,Philip B. McGlave,John E. Wagner	376
17	The Biology of Natural Killer Cells and Implications for Therapy of Human Disease 2001 ·Journal of Hematotherapy & Stem Cell Research ·E. Gabriela Chiorean,Jeffrey S. Miller	27
18	Production of Human Natural Killer Cells for Adoptive Immunotherapy Using a Computer-Controlled Stirred-Tank Bioreactor 1996 ·Journal of Hematotherapy ·(unknown),Anna Europa,Wei‐Shou Hu,Jeffrey S. Miller	33
19	Natural Killer Cell Proliferation Is Dependent on Human Serum and Markedly Increased Utilizing an Enriched Supplemented Basal Medium 1995 ·Journal of Hematotherapy ·(unknown),(unknown),Wei‐Shou Hu,Jeffrey S. Miller	38
20	Expansion and Activation of Human Natural Killer Cells for Autologous Therapy 1994 ·Journal of Hematotherapy ·Jeffrey S. Miller,Catherine M. Verfaillie,Philip B. McGlave	6

About Jeffrey S. Miller

Jeffrey S. Miller is a scholar working on Hematology, Immunology and Oncology, having authored 607 papers that have together received 32.9k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (348 papers), Hematopoietic Stem Cell Transplantation (176 papers) and T-cell and B-cell Immunology (159 papers). The work is most often cited by research in Immunology (21.4k citations), Hematology (9.4k citations) and Oncology (11.8k citations). Jeffrey S. Miller has collaborated with scholars based in United States, United Kingdom and Sweden. Frequent co-authors include Daniel J. Weisdorf, Bruce R. Blazar, Sarah Cooley, Michael R. Verneris, Todd E. DeFor, John E. Wagner, Philip B. McGlave, Valarie McCullar, Martin Felices and Catherine M. Verfaillie. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact